Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.32 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400964 | 0.88 | ECE1 (0.44) | ECE1TACR1KCNH2PLA2G4APLA2G6 | |
| SCHEMBL7146865 | 0.86 | ECE1 (0.51) | ECE1PLA2G4APLA2G6 | |
| SCHEMBL5407311 | 0.86 | ECE1 (0.51) | ECE1PLA2G4APLA2G6 | |
| SCHEMBL5411771 | 0.84 | ECE1 (0.41) | ECE1AGTR2TACR1KCNH2HRH3 | |
| SCHEMBL5404278 | 0.83 | ECE1 (0.51) | ECE1TACR1RORCPLA2G4APLA2G6 | |
| SCHEMBL5415467 | 0.81 | ECE1 (0.51) | ECE1PLA2G4APLA2G6 | |
| SCHEMBL5415747 | 0.81 | ECE1 (0.37) | ECE1RORC | |
| SCHEMBL5407100 | 0.81 | ECE1 (0.47) | ECE1PLA2G4APLA2G6 | |
| SCHEMBL5407104 | 0.81 | ECE1 (0.47) | ECE1PLA2G4APLA2G6 | |
| SCHEMBL5413340 | 0.80 | ECE1 (0.60) | ECE1PLA2G4APLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | AEBI JOHANNES (CH) | 2004-12-02 | — | — | US | disclosed |
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199569-A1 | Pyrrolidine derivatives | AEBI JOHANNES (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1303486-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002008185-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199569-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | ECE1 4/4885AGTR2 493/4885TACR1 391/4885 |
| US-20020040146-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | ECE1 4/4885AGTR2 493/4885TACR1 391/4885 |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | MMP1, PEPD, MMP25 | ECE1 33/4885AGTR2 390/4885TACR1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.